LABS — Medipharm Labs Share Price
0.000.00%
Last trade - 00:00- CA$35.29m
- CA$23.98m
- CA$41.96m
- 63
- 64
- 80
- 78
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 0.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25% | ||
| Return on Equity | -22.24% | ||
| Operating Margin | -25.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 36.01 | 21.71 | 22.12 | 33.06 | 41.96 | 46.27 | 53.57 | -20.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.
Directors
- Chris Taves CHM
- Keith Strachan PRE
- Bryan Howcroft CEO
- Greg Hunter CFO
- Warren Everitt CEX
- Shelley Martin LED
- Chris Halyk IND
- Miriam McDonald IND
- Paul Tam IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 23rd, 2017
- Public Since
- February 9th, 2018
- No. of Employees
- 161
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 415,138,973
- Address
- 151 John Street, BARRIE, L4N 2L1
- Web
- https://www.medipharmlabs.com/
- Phone
- +1 7057197425
- Auditors
- MNP LLP
Upcoming Events for LABS
Medipharm Labs Corp Annual Shareholders Meeting
Q2 2025 Medipharm Labs Corp Earnings Release
Similar to LABS
Aptose Biosciences
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
What is the Medipharm Labs share price?
As of Today at 21:58 UTC, shares in Medipharm Labs are trading at CA$0.09. This share price information is delayed by 15 minutes.
How has the Medipharm Labs share price performed this year?
Shares in Medipharm Labs last closed at CA$0.09 and the price had moved by +6.25% over the past 365 days. In terms of relative price strength the Medipharm Labs share price has underperformed the Toronto Stock Exchange 300 Composite Index by -4.23% over the past year.
What are the analyst and broker recommendations for Medipharm Labs?
The overall consensus recommendation for Medipharm Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medipharm Labs dividend yield?
Medipharm Labs does not currently pay a dividend.
Does Medipharm Labs pay a dividend?
Medipharm Labs does not currently pay a dividend.
When does Medipharm Labs next pay dividends?
Medipharm Labs does not currently pay a dividend.
How do I buy Medipharm Labs shares?
To buy shares in Medipharm Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medipharm Labs?
As of the previous close price of CA$0.09, shares in Medipharm Labs had a market capitalisation of CA$35.29m.
Where are Medipharm Labs shares listed?
Here are the trading details for Medipharm Labs:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: LABS
What kind of share is Medipharm Labs?
Based on an overall assessment of its quality, value and momentum Medipharm Labs is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medipharm Labs share price forecast for 2025?
The analyst consensus target price for shares in Medipharm Labs is CA$0.10. That is 17.65% above the last closing price of CA$0.09.
Analysts covering Medipharm Labs currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.01 for the next financial year.
Find out moreWhat is the trend in the Medipharm Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medipharm Labs. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +15.82%.
As of the last closing price of CA$0.09, shares in Medipharm Labs were trading +18.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medipharm Labs PE Ratio?
The Medipharm Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medipharm Labs?
Medipharm Labs' management team is headed by:
- Chris Taves - CHM
- Keith Strachan - PRE
- Bryan Howcroft - CEO
- Greg Hunter - CFO
- Warren Everitt - CEX
- Shelley Martin - LED
- Chris Halyk - IND
- Miriam McDonald - IND
- Paul Tam - IND